Why the study?
This study sought to assess the performance of a novel liquid nitrogen-driven cryoballoon ablation system and evaluate its safety and efficacy for treating drug-resistant paroxysmal atrial fibrillation.
Does a novel liquid nitrogen cryoballoon ablation system safely and effectively achieve pulmonary vein isolation and treatment success in patients with drug-resistant paroxysmal atrial fibrillation?
Does a novel liquid nitrogen cryoballoon ablation system safely and effectively achieve pulmonary vein isolation and treatment success in patients with drug-resistant paroxysmal atrial fibrillation?
A novel liquid nitrogen-driven cryoballoon ablation system demonstrated high immediate procedural success and an 82.6% 12-month treatment success rate in patients with drug-resistant paroxysmal atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports feasibility of novel cryoballoon in paroxysmal AF; hypothesis-generating pending randomized comparisons.
Background: Cryoballoon ablation (CBA) has emerged as an effective treatment for atrial fibrillation (AF). Objectives: This study sought to assess the performance of a novel liquid nitrogen-driven CBA system and evaluate its safety and efficacy in the treatment of drug-resistant paroxysmal atrial fibrillation (PAF). Methods: This was a prospective multicenter single-arm clinical trial with 10 participating tertiary hospitals enrolling 176 patients with PAF. All participants received liquid nitrogen-driven CBA developed by the Cryofocus Medtech Company. Scheduled follow-up was performed before discharge and 3 months, 6 months, and 12 months after CBA. The primary endpoints were defined as 1) treatment success (freedom from antiarrhythmic drugs and atrial tachycardia at 12 months after CBA); and 2) immediate success rate of pulmonary vein isolation. The safety endpoint was the incidence of device- and procedure-related adverse events (AEs) and all-cause mortality. Results: A total of 172 participants were included, with an average age of 59.22 ± 9.25 years and 99 (57.56%) of them men. Immediate success rate was 97.67% (95% CI: 94.15%-99.36%) and 12-month treatment success rate was 82.56% (95% CI: 76.89%-88.23%), including a late recurrence rate of 13.61%. Incidences of device- and procedure-related AEs were 2.27% and 25.00%, respectively. Phrenic nerve palsy (PNP) occurred in 6 patients, of which 5 recovered during follow-up. Although the incidence of total severe AEs was 17.05%, including an all-cause mortality of 0.57%, only 1 case of permanent PNP was related to the CBA procedure. Conclusions: This premarketing prospective multicenter single-arm clinical trial demonstrated that the liquid nitrogen cryoablation system is safe and effective in the treatment of PAF.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: